Table 5.
Association of uncontrolled hypertension and metabolic risk factors among hypertension patients from baseline and the follow-up*.
| Variable | ATP III MS definition | Modified ATP III MS definition | IDF MS definition | JIS MS definition | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI)a | OR (95% CI)b | OR (95% CI)a | OR (95% CI)b | OR (95% CI)a | OR (95% CI)b | OR (95% CI)a | OR (95% CI)b | |
| Central obesity vs. normal waist circumferencec | 1.57 (1.13–2.46) | 1.41 (1.17–1.71) | 1.68 (1.21–2.60) | 1.46 (1.23–1.72) | 1.65 (1.25–3.18) | 1.30 (1.10–1.55) | 1.56 (1.14–3.78) | 1.28 (1.07–1.53) |
| Abnormal vs. normal TG | 1.21 (1.08–1.74) | 1.32 (1.11–1.56) | 1.21 (1.08–1.74) | 1.32 (1.11–1.56) | 1.21 (1.08–1.74) | 1.32 (1.11–1.56) | 1.19 (1.06–1.69) | 1.32 (1.11–1.56) |
| Abnormal vs. normal HDL-c | 1.17 (1.07–2.34) | 1.21 (1.07–1.41) | 1.17 (1.07–2.34) | 1.21 (1.07–1.41) | 1.17 (1.07–2.34) | 1.21 (1.07–1.41) | 1.16 (1.04–2.80) | 1.19 (1.05–1.38) |
| Abnormal vs. normal glucose | 1.39 (1.11–2.11) | 1.31 (1.11–1.55) | 1.28 (1.04–1.77) | 1.38 (1.15–1.65) | 1.28 (1.04–1.77) | 1.38 (1.15–1.65) | 1.28 (1.04–1.77) | 1.38 (1.15–1.65) |
| MS | 2.02 (1.12–3.09) | 1.60 (1.28–1.96) | 1.96 (1.13–3.00) | 1.60 (1.37–1.97) | 1.76 (1.48–2.39) | 1.55 (1.15–1.90) | 1.71 (1.16–2.82) | 1.54 (1.13–1.90) |
| Metabolic disorder factors | ||||||||
| 0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1 | 1.41 (1.01–2.82) | 1.19 (0.91–1.56) | 1.47 (1.04–2.67) | 1.19 (0.91–1.56) | 1.41 (1.17–3.38) | 1.24 (1.00–1.59) | 1.56 (0.91–2.76) | 1.28 (1.02–2.04) |
| 2 | 2.15 (1.34–3.37) | 1.87 (1.01–2.20) | 2.03 (1.28–3.17) | 1.89 (1.43–2.26) | 1.66 (1.04–2.64) | 1.42 (1.09–1.61) | 2.11 (1.44–3.74) | 1.98 (1.43–2.41) |
| ≥3 | 3.10 (2.23–3.78) | 3.21 (2.65–3.97) | 3.07 (2.67–3.98) | 2.97 (2.35–3.57) | 2.57 (1.29–3.13) | 2.41 (1.72–2.78) | 2.68 (1.64–3.66) | 2.34 (1.76–3.05) |
| P for trend | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |
| Area under the receiver operating characteristic curve (95% CI) | 0.63 (0.56–0.69) | 0.56 (0.54–0.58) | 0.62 (0.55–0.68) | 0.57 (0.54–0.59) | 0.61 (0.55–0.68) | 0.55 (0.53–0.57) | 0.63 (0.56–0.70) | 0.56 (0.53–0.58) |
*Adjusted for body mass index (not including in model c), vegetable consumption, fruit consumption, education, income, farmer status, smoking status and drinking status.
a1,515 patients with hypertension who received drug therapy among the 2,912 patients at baseline, b2,912 patients with hypertension who were all receiving antihypertension therapy at the 1-year follow-up.
OR: odds ratio, 95% CI: 95% confidence interval, TG: triglycerides; HDL-c: high-density lipoprotein cholesterol, MS: metabolic syndrome, ATP III: the Adult Treatment Panel III (part of the 2001 US Third Report of the National Cholesterol Education Program), Modified ATP III: the 2004 modification of the ATP III for Asian populations, IDF: the 2005 criteria from the International Diabetes Federation, JIS: the 2009 criteria from the Joint Interim Statement.